Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in High Risk Oral Premalignant Lesions
NCT04504552Phase 2Unknown
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jul 2020
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in Oral Precancerous Lesions, sponsored by ASST Spedali Civili di Brescia. Status: unknown.
02
Drugs
avelumab
03
Conditions
Oral Precancerous Lesions
Beyond the preview
Go deeper on NCT04504552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504552.